Alumis Inc.

XNASHealth care

Last traded price · USD

$6.43

−1.83%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 19:22 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $6.55
Volume: 604
Day's high: —
Day's low: —

In brief

Alumis Inc. is a health care company listed on Nasdaq, valued at about $832M.
Its shares closed at $6.55 on 4 Nov 2026, up 44.0% over the past year.
From India you can buy ALMS in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Alumis Inc. (ALMS) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole ALMS share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade ALMS options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: −5.5% (SPY −1.6%, XLV +13.5%). 3 months: −75.8% (SPY −0.4%, XLV +15.5%). 1 year: +44.0% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: ALMS, SPY and XLV · as of 4 Nov 2026
48.9% above its 52-week low
Closed at $6.55 on 4 Nov 2026: 79.1% below the 52-week high of $31.35 (8 Jul 2026) and 48.9% above the low of $4.40 (7 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $6.55 was 25.8% below its 50-day average ($8.82) and 69.0% below its 200-day average ($21.15). It has closed below the 200-day for 47 sessions, since 31 Aug 2026. The 50-day average crossed below the 200-day on 18 Sep 2026, 33 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Short interest at 8.6% of shares outstanding
11.1M shares were sold short at the 15 Oct 2026 settlement, 8.6% of the 129.4M shares outstanding; covering them would take 4.9 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−5.5%

6 months−74.3%

1 year+44.0%

5 years—

Newswire

About

Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.

Website

Notable moves

September 1, 2026
−56.58%
January 6, 2026
+95.31%
April 2, 2025
+35.91%

Alumis Inc.

XNASHealth care

Last traded price · USD

$6.43

−1.83%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 19:22 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $6.55
Volume: 604
Day's high: —
Day's low: —

In brief

Alumis Inc. is a health care company listed on Nasdaq, valued at about $832M.
Its shares closed at $6.55 on 4 Nov 2026, up 44.0% over the past year.
From India you can buy ALMS in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Alumis Inc. (ALMS) shares from India?

Do I need the price of a whole ALMS share to invest?

How much can I invest in US stocks in a year?

Can I trade ALMS options or futures?

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: −5.5% (SPY −1.6%, XLV +13.5%). 3 months: −75.8% (SPY −0.4%, XLV +15.5%). 1 year: +44.0% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: ALMS, SPY and XLV · as of 4 Nov 2026
48.9% above its 52-week low
Closed at $6.55 on 4 Nov 2026: 79.1% below the 52-week high of $31.35 (8 Jul 2026) and 48.9% above the low of $4.40 (7 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $6.55 was 25.8% below its 50-day average ($8.82) and 69.0% below its 200-day average ($21.15). It has closed below the 200-day for 47 sessions, since 31 Aug 2026. The 50-day average crossed below the 200-day on 18 Sep 2026, 33 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
Short interest at 8.6% of shares outstanding
11.1M shares were sold short at the 15 Oct 2026 settlement, 8.6% of the 129.4M shares outstanding; covering them would take 4.9 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−5.5%

6 months−74.3%

1 year+44.0%

5 years—

Newswire

About

Website

Notable moves

September 1, 2026
−56.58%
January 6, 2026
+95.31%
April 2, 2025
+35.91%

Alumis Inc.

Alumis Inc. in brief

Ahead of SPY and its sector fund XLV over 1 year

48.9% above its 52-week low

Below its 50- and 200-day averages

Short interest at 8.6% of shares outstanding

Alumis Inc.

Alumis Inc. in brief

Ahead of SPY and its sector fund XLV over 1 year

48.9% above its 52-week low

Below its 50- and 200-day averages

Short interest at 8.6% of shares outstanding